What IV iron dose should be given to an adult on hemodialysis to raise ferritin above 200 ng/mL and maintain transferrin saturation above 20 % without exceeding ferritin 800 ng/mL?

IV Iron Dosing for Hemodialysis Patients

For adults on hemodialysis, administer 100–200 mg of intravenous iron monthly to maintain ferritin between 200–800 ng/mL and transferrin saturation (TSAT) between 20–40%. 1

Initiation Criteria

Start IV iron when either of these conditions is met:

• Ferritin ≤ 200 ng/mL 1
• TSAT ≤ 20% (even if ferritin is 200–800 ng/mL, indicating functional iron deficiency) 1

The older NKF-K/DOQI guidelines used lower thresholds (ferritin ≥100 ng/mL, TSAT ≥20%) 2, but more recent evidence supports higher targets specifically for hemodialysis patients to optimize erythropoiesis and reduce ESA requirements 1.

Target Parameters During Maintenance

Your goals are:

• Ferritin: 200–800 ng/mL 1
• TSAT: 20–40% 1

These targets balance adequate iron availability against the risk of iron overload 2. Ferritin levels between 300–800 ng/mL have been common in dialysis patients without evidence of adverse iron-mediated effects 2.

Specific Dosing Regimens

Standard Maintenance Approach

• 100–200 mg IV iron per month when ferritin ≤200 ng/mL or TSAT ≤20% 1
• The higher end (200 mg monthly) significantly reduces ESA requirements more than 100 mg monthly 3, 4

Evidence-Based Dosing Options

Option 1: Iron Dextran (Historical Protocol)

• 10 doses of 50 mg over 10 weeks (total 500 mg per quarter) 2
• Equivalent to approximately 167 mg/month

Option 2: Iron Gluconate

• 8 doses of 125 mg over 8 weeks (total 1000 mg per quarter) 2
• Equivalent to approximately 333 mg/month
• Alternative: 8 doses of 62.5 mg over 8 weeks 2

Option 3: Iron Sucrose (PIVOTAL Trial - Highest Quality Evidence)

• Proactive high-dose regimen: 400 mg monthly unless ferritin >700 μg/L or TSAT ≥40% 5
• This approach demonstrated superiority over reactive low-dose therapy (0–400 mg triggered only when ferritin <200 μg/L or TSAT <20%) 5
• Median actual dose delivered: 264 mg/month 5
• Resulted in 29% reduction in ESA dose and 15% reduction in primary cardiovascular/mortality endpoints 5

Option 4: Ferric Carboxymaltose

• 100 mg or 200 mg every 4 weeks 6
• Can be given up to 1000 mg as single infusion 1

When to Hold or Stop IV Iron

Mandatory hold criteria:

• Ferritin ≥800 ng/mL AND TSAT ≥20% 1
• TSAT ≥40% regardless of ferritin level 1

The upper ferritin limit of 800 ng/mL is based on evidence that patients are unlikely to respond with further hemoglobin increases or ESA dose reductions beyond this level 2. While TSAT up to 50% has no known risk, there is no physiologic rationale for maintaining levels above 40% 2.

Monitoring Schedule

• Check ferritin and TSAT every 3 months during stable maintenance therapy 2
• Wait 4–8 weeks after dose adjustments before rechecking iron parameters 1
• Critical timing consideration: Do not check ferritin within 4 weeks of IV iron administration, as circulating iron causes falsely elevated results 1
  • After 100 mg ferric carboxymaltose: ferritin remains elevated for 2 weeks 6
  • After 200 mg ferric carboxymaltose: ferritin remains elevated for 3 weeks 6

Safety Considerations

Test Dosing

• Iron dextran: Requires one-time 25 mg test dose in adults before initiating therapy 2
• Newer formulations (ferric carboxymaltose, ferumoxytol, ferric derisomaltose): Generally do not require test doses 1
• Iron gluconate: One-time 25 mg test dose recommended 2

Dose-Related Toxicity Concerns

While the PIVOTAL trial showed safety with proactive high-dose therapy 5, observational data suggest caution with chronic excessive dosing:

• Monthly doses >200 mg sustained long-term (>1 year) have been associated with increased mortality and cardiovascular events in some observational studies 2
• Doses >300 mg/month showed increased mortality risk (HR 1.13–1.18) in the DOPPS study 2
• The Japanese experience suggests doses >200 mg/month increased acute cardiocerebrovascular disease (HR 6.02) 2

Common pitfall: These observational studies had longer follow-up (1–2 years) than the methodologically superior PIVOTAL RCT (median 2.1 years), creating some uncertainty about very long-term high-dose therapy 2, 5.

Infection Risk

Current evidence shows no increased infection rate with high-dose versus low-dose IV iron regimens 5.

Interpretation Nuances

Ferritin is an acute-phase reactant and may be falsely elevated by inflammation even when true iron deficiency exists 1. When ferritin is high but TSAT is low, TSAT provides the more reliable guide for iron therapy decisions 1.

Practical Algorithm

1. Check baseline ferritin and TSAT
2. If ferritin ≤200 ng/mL OR TSAT ≤20%: Start IV iron
3. Choose regimen based on ESA requirements:
   • High ESA needs or suboptimal hemoglobin: Use 200–400 mg/month proactive approach 1, 5
   • Adequate hemoglobin control: Use 100–200 mg/month 1
4. Hold iron if ferritin ≥800 ng/mL or TSAT ≥40% 1
5. Recheck parameters every 3 months (timing blood draw >4 weeks after last iron dose) 2, 1, 6
6. Adjust dose to maintain ferritin 200–800 ng/mL and TSAT 20–40% 1